share_log

Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

Corbus Pharmicals 將參加 2024 年加拿大皇家銀行資本市場全球醫療保健會議
Corbus Pharmaceuticals ·  05/09 00:00

NORWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the 2024 RBC Capital Markets Global Healthcare Conference to be held May 14-15, 2024 in New York, NY.

馬薩諸塞州諾伍德,2024年5月9日(GLOBE NEWSWIRE)——Corbus Pharmicals Holdings, Inc.(納斯達克股票代碼:CRBP)(“Corbus” 或 “公司”)今天宣佈,Corbus首席執行官尤瓦爾·科恩博士將在2024年5月14日至15日在紐約舉行的2024年加拿大皇家銀行資本市場全球醫療保健會議上參加爐邊談話和一對一投資者會議。

2024 RBC Capital Markets Global Healthcare Conference
Format: Fireside chat and one-on-one investor meetings
Presentation Date: Tuesday, May 14, 2024
Presentation Time: 9:30 a.m. ET
Webcast: Click Here

2024 加拿大皇家銀行資本市場全球醫療保健會議
形式:爐邊聊天和一對一投資者會議
演講日期:2024 年 5 月 14 日星期二
演講時間:美國東部時間上午 9:30
網絡直播: 點擊這裏

About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus' pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.

關於 Corbus
Corbus Pharmicals Holdings, Inc. 是一家擁有多元化投資組合的精準腫瘤學公司,致力於通過將創新的科學方法引入廣爲人知的生物途徑來幫助人們戰勝嚴重疾病。Corbus 的產品線包括 CRB-701,一種靶向癌細胞上表達 Nectin-4 以釋放細胞毒性有效載荷的下一代抗體偶聯物,CRB-601,一種阻斷癌細胞上表達的 TGFβ 激活的抗整合素單克隆抗體,以及用於治療肥胖的高度外周受限的 CB1 受體反向激動劑 CRB-913。Corbus 總部位於馬薩諸塞州諾伍德。有關 Corbus 的更多信息,請訪問 corbuspharma.com。通過以下方式聯繫我們 推特領英Facebook

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

前瞻性陳述
本新聞稿包含1933年《證券法》第27A條和經修訂的《1934年證券交易法》和經修訂的私人證券訴訟改革法第21E條所指的某些前瞻性陳述,包括與公司的試驗結果、產品開發、臨床和監管時間表、市場機會、競爭地位、可能或假設的未來經營業績、業務戰略、潛在增長機會以及其他本質上具有預測性的陳述有關的前瞻性陳述。這些前瞻性陳述基於當前對我們經營的行業和市場的預期、估計、預測和預測以及管理層當前的信念和假設。

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

這些陳述可以通過使用前瞻性表達來識別,包括但不限於 “期望”、“預期”、“打算”、“計劃”、“相信”、“估計”、“潛力”、“預測”、“項目”、“應該”、“將” 以及類似的表達方式以及這些術語的否定詞。這些陳述與未來事件或我們的財務業績有關,涉及已知和未知的風險、不確定性以及我們的運營、臨床開發計劃和時間表中的其他因素,這些因素可能導致實際業績、業績或成就與前瞻性陳述所表達或暗示的任何未來業績、業績或成就存在重大差異。這些因素包括公司向美國證券交易委員會提交的文件中列出的因素。提醒潛在投資者不要過分依賴此類前瞻性陳述,這些陳述僅代表截至本新聞稿發佈之日。公司沒有義務公開更新任何前瞻性陳述,無論是由於新信息、未來事件還是其他原因。

All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.

所有產品名稱、徽標、品牌和公司名稱均爲其各自所有者的商標或註冊商標。它們的使用並不意味着這些公司的隸屬關係或認可。

INVESTOR CONTACT:

投資者聯繫人:

Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
Sean.moran@corbuspharma.com

肖恩·莫蘭
首席財務官
柯布斯製藥
Sean.moran@corbuspharma.com

Bruce Mackle
Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com

布魯斯·麥克爾
董事總經理
LifeSci 顧問有限公司
bmackle@lifesciadvisors.com

Primary Logo

Source: Corbus Pharmaceuticals Holdings, Inc.

資料來源:Corbus 製藥控股有限公司

Released May 9, 2024

2024 年 5 月 9 日發佈

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論